Seminars in Pediatric Neurology
Volume 13, Issue 3 , Pages 176-181, September 2006

Neuroferritinopathy

  • John Burn, MD, FRCP, FRCPCH, FRCOG, FMed Sci

      Affiliations

    • Corresponding Author InformationAddress reprint requests to John Burn, MD, FRCP, FRCPCH, FRCOG, FMed Sci, Institute of Human Genetics, Newcastle University, Central Parkway, Newcastle on Tyne NE1 3BZ, UK.
  • ,
  • Patrick F. Chinnery, MD, PhD, FRCP

Institute of Human Genetics, Newcastle University, Newcastle on Tyne, UK.

Neuroferritinopathy (MIM 606159, also labeled hereditary ferritinopathy and neurodegeneration with brain iron accumulation type 2, NBIA2) is an adult-onset progressive movement disorder caused by mutations in the ferritin light chain gene (FTL1). Four pathogenic mutations in FTL1 have been described to date; 460insA was our original founder mutation in Cumbria, North West England, where it arose before 1800. The same mutation appears to have arisen separately in France. The resulting altered reading frame extends the peptide, disrupting the ferritin dodecahedron structure and causing accumulation of ferritin and iron, primarily in central neurons. A wide range of neurologic symptoms may occur; 50% present with chorea, 43% with limb dystonia, and 7% with Parkinsonian features. The disorder provides a direct link between disordered iron storage and a neurodegenerative disease, opening new avenues for treatment by altering brain iron stores in addition to symptomatic treatments such as local Botulinum toxin and oral anti oxidants.

Keywords: iron, ferritin, basal, ganglia, neuroferritinopathy

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 10.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported in part by the Newcastle Hospitals Special Trustees. PFC is a Wellcome Trust Senior Fellow in Clinical Science and receives additional grant support from The Wellcome Trust, Ataxia UK, The Alzheimer’s Research Trust, the Association Francaise Contre les Myopathies, the United Mitochondrial Diseases Foundation, and the EU FP6 program EUmitocombat and MITOCIRCLE.

PII: S1071-9091(06)00105-7

doi:10.1016/j.spen.2006.08.006

Seminars in Pediatric Neurology
Volume 13, Issue 3 , Pages 176-181, September 2006